# Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia

> **NCT01235117** · PHASE2 · COMPLETED · sponsor: **University of Leeds** · enrollment: 30 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** azacitidine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01235117
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235117, "Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01235117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*